{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T19:04:23Z","timestamp":1788721463994,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.leukres.2023.107306","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T21:29:07Z","timestamp":1683235747000},"page":"107306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Acute myeloid leukemia in the medically unfit elderly patients"],"prefix":"10.1016","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6551-8853","authenticated-orcid":false,"given":"Joseph","family":"Edmund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz Joemon","family":"Thaliath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil","family":"Meleveedu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.leukres.2023.107306_bib1","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3324\/haematol.2008.000497","article-title":"Treatment of older adults with acute myeloid leukemia: state of the art and current perspectives","volume":"93","author":"Sekeres","year":"2008","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.leukres.2023.107306_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/21556660.2018.1492925","article-title":"Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML)","volume":"7","author":"Acharya","year":"2018","journal-title":"J. Drug Assess."},{"issue":"18","key":"10.1016\/j.leukres.2023.107306_bib3","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish acute leukemia registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2023.107306_bib4","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/cncr.21723","article-title":"Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.leukres.2023.107306_bib5","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/leu.2017.109","article-title":"Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape","volume":"31","author":"Silva","year":"2017","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.leukres.2023.107306_bib6","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00432-006-0115-7","article-title":"Impairment in functional status and survival in patients with acute myeloid leukaemia","volume":"132","author":"Wedding","year":"2006","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2023.107306_bib7","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3324\/haematol.2021.278802","article-title":"Randomized controlled trial of geriatric consultation versus standard care in older adults with hematologic malignancies","volume":"107","author":"DuMontier","year":"2022","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.leukres.2023.107306_bib8","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/ejh.13570","article-title":"Impact of a comprehensive geriatric assessment on decision-making in older patients with hematological malignancies","volume":"106","author":"Garric","year":"2021","journal-title":"Eur. J. Haematol."},{"issue":"12","key":"10.1016\/j.leukres.2023.107306_bib9","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","article-title":"Survival for older patients with acute myeloid leukemia: a population-based study","volume":"97","author":"Oran","year":"2012","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.leukres.2023.107306_bib10","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.3324\/haematol.13309","article-title":"Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia","volume":"93","author":"Malfuson","year":"2008","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.leukres.2023.107306_bib11","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1002\/cncr.32439","article-title":"Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: a population-level analysis","volume":"125","author":"Zeidan","year":"2019","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.leukres.2023.107306_bib12","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026948","article-title":"DNA hypomethylating drugs in cancer therapy","volume":"7","author":"Sato","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"3","key":"10.1016\/j.leukres.2023.107306_bib13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2023.107306_bib14","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.leukres.2023.107306_bib15","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.leukres.2023.107306_bib16","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1182\/bloodadvances.2020001779","article-title":"Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States","volume":"4","author":"Zeidan","year":"2020","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.leukres.2023.107306_bib17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood.2022015832","article-title":"Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy","volume":"140","author":"Zeidan","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2023.107306_bib18","first-page":"307","volume":"38","author":"Ye","year":"2017","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"25","key":"10.1016\/j.leukres.2023.107306_bib19","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.leukres.2023.107306_bib20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2023.107306_bib21","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.22496","article-title":"A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment","volume":"109","author":"Burnett","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.leukres.2023.107306_bib22","first-page":"35","article-title":"Leucemia mieloide aguda en mayores de 70 a\u00f1os. Experiencia utilizando tratamiento con Ara-C a bajas dosis [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment]","volume":"43","author":"Rodr\u00edguez","year":"1998","journal-title":"Sangre"},{"issue":"5","key":"10.1016\/j.leukres.2023.107306_bib23","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2014-08-551499","article-title":"How I treat the older patient with acute myeloid leukemia","volume":"125","author":"Ossenkoppele","year":"2015","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.leukres.2023.107306_bib24","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/bloodadvances.2019000937","article-title":"Venetoclax for AML: changing the treatment paradigm","volume":"3","author":"Pollyea","year":"2019","journal-title":"Blood Adv."},{"issue":"10","key":"10.1016\/j.leukres.2023.107306_bib25","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.leukres.2023.107306_bib26","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.leukres.2023.107306_bib27","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.leukres.2023.107306_bib28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2023.107306_bib29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1200\/JCO.20.01632","article-title":"Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.leukres.2023.107306_bib30","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.leukres.2023.107306_bib31","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib\/II Study","volume":"37","author":"Wei","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.leukres.2023.107306_bib32","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.leukres.2023.107306_bib33","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.20.00572","article-title":"Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy","volume":"38","author":"Chua","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2023.107306_bib34","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.leukres.2023.107306_bib35","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1002\/cncr.30949","article-title":"Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies","volume":"123","author":"Abaza","year":"2017","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.leukres.2023.107306_bib36","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/bloodadvances.2018027409","article-title":"Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study","volume":"3","author":"Garcia-Manero","year":"2019","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.leukres.2023.107306_bib37","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/16078454.2021.1962047","article-title":"Efficacy and safety of cladribine addition to induction treatment of newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis","volume":"26","author":"Pan","year":"2021","journal-title":"Hematology"},{"issue":"3","key":"10.1016\/j.leukres.2023.107306_bib38","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1200\/JCO.1992.10.3.364","article-title":"2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia","volume":"10","author":"Santana","year":"1992","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2023.107306_bib39","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/blood.V87.1.256.256","article-title":"Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions","volume":"87","author":"Gandhi","year":"1996","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2023.107306_bib40","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.1016\/S2352-3026(18)30132-7","article-title":"Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial","volume":"5","author":"Kadia","year":"2018","journal-title":"Lancet Haematol."},{"issue":"6","key":"10.1016\/j.leukres.2023.107306_bib41","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1535-7163.MCT-16-0876","article-title":"FLT3 inhibitors in acute myeloid leukemia: current status and future directions","volume":"16","author":"Larrosa-Garcia","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.leukres.2023.107306_bib42","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41408-022-00670-0","article-title":"Hypomethylating agent and venetoclax with FLT3 inhibitor \"triplet\" therapy in older\/unfit patients with FLT3 mutated AML","volume":"12","author":"Yilmaz","year":"2022","journal-title":"Blood Cancer J."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623005714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623005714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:03:39Z","timestamp":1758935019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212623005714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":42,"alternative-id":["S0145212623005714"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107306","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute myeloid leukemia in the medically unfit elderly patients","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107306","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107306"}}